New melanoma drug gives 63 percent reduction in risk of death compared to dacarbazine
17 Jun 2011
New melanoma drug gives 63 percent reduction in risk of death compared to dacarbazine
Ipilimumab improves survival in metastatic melanoma
Highlights from 2011 and ASCO’s future
ASCO 2011 highlights
The future of medicine: personalised
Reducing global cancer mortality
The Cancer Genome Atlas (TCGA)
Combination therapy targeting MEK and PI3K pathways shows anti-tumour activity
Ethical considerations surrounding cancer in the elderly and the pros and cons of web-based resources
Treatment of brain metastases in melanoma patients
Sarah Cannon Research Institute research developments at ASCO 2010
Clinical benefits and side effects of ipilimumab in melanoma patients